Summary What is already known about this topic? HIV preexposure prophylaxis (PrEP) reduces HIV incidence; however, adherence to available PrEP regimens is suboptimal. In June 2025, FDA approved injectable lenacapavir (LEN) administered every 6 months as HIV PrEP, based on results from two randomized controlled trials (RCTs) that reported LEN efficacy at reducing HIV infection as 100% among females and …
Read More »Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025
